Moderna, Inc. $MRNA Shares Bought by Vise Technologies Inc.

Posted by Francis Steltz on Nov 7th, 2026

Vise Technologies Inc. boosted its stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 63.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,879 shares of the company’s stock after acquiring an additional 3,432 shares during the period. Vise Technologies Inc.’s holdings in Moderna were worth $1,710,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of Moderna in the 2nd quarter worth about $2,142,877,000. Theleme Partners LLP purchased a new position in shares of Moderna during the second quarter valued at about $564,272,000. Wellington Management Group LLP raised its stake in Moderna by 4.4% in the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after buying an additional 103,977 shares in the last quarter. First Trust Advisors LP raised its stake in Moderna by 59.3% in the first quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock worth $121,549,000 after buying an additional 891,072 shares in the last quarter. Finally, Merck & Co. Inc. purchased a new stake in Moderna in the second quarter worth about $161,642,545. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on MRNA shares. The Goldman Sachs Group lifted their price objective on Moderna from $120.00 to $137.00 and gave the company a “neutral” rating in a research report on Thursday, October 15th. CLSA upgraded Moderna to an “outperform” rating in a research note on Friday, August 28th. Piper Sandler restated an “overweight” rating and set a $230.00 price target (up from $167.00) on shares of Moderna in a research report on Monday, October 26th. Barclays upped their price target on Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday, August 24th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $150.00 price objective (up from $60.00) on shares of Moderna in a report on Wednesday, August 19th. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $107.10.

Read Our Latest Stock Analysis on MRNA

Moderna Stock Up 5.3%

Shares of MRNA traded up $12.73 during mid-day trading on Friday, reaching $254.19. The company had a trading volume of 16,295,043 shares, compared to its average volume of 18,981,452. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The company has a market capitalization of $101.48 billion, a price-to-earnings ratio of -31.81 and a beta of 1.16. The firm has a 50-day moving average price of $191.85 and a 200 day moving average price of $91.51. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $267.50.

Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The firm’s revenue for the quarter was up 29.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.51) EPS. On average, sell-side analysts forecast that Moderna, Inc. will post -6.11 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Jamey Mock sold 34,836 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the sale, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider owned 74,129 shares of the company’s stock, valued at $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is currently owned by corporate insiders.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Moderna reported third-quarter revenue of $1.31 billion, up 29.2% year over year, and earnings of $0.38 per share, far ahead of analysts’ expectations for a loss. Stronger overseas COVID-19 vaccine sales helped drive the results. Reuters report on revenue and demand
Positive Sentiment: Management raised its 2026 revenue-growth forecast to 15%–25%, from a prior outlook of up to 10%. The company also said it plans to reduce research and development spending, supporting its near-term financial performance. CNBC outlook report
Positive Sentiment: Health Canada authorized Moderna’s seasonal flu and flu-COVID combination vaccines for adults 50 and older, opening a potential new market for its mRNA products. CBC report on Canadian approvals
Positive Sentiment: Investors are also watching prospects for Moderna’s cancer vaccine: CEO Stéphane Bancel said it could have potential beyond melanoma. That adds pipeline excitement, though future commercial value remains uncertain. Yahoo Finance report on cancer vaccine prospects
Neutral Sentiment: Moderna and GSK settled a patent dispute involving Moderna’s COVID and RSV shots. The settlement removes a source of legal uncertainty, but the available report does not specify its financial terms. Reuters report on patent settlement
Negative Sentiment: The sharp rally has heightened concerns that expectations for the cancer-vaccine pipeline may be running ahead of near-term revenue potential. Moderna’s longer-term prospects still depend on sustaining vaccine sales and turning pipeline advances into commercial products. Barron’s analysis of Moderna’s earnings and valuation

Moderna Profile

(Free Report)

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.